Merck (MRK) Receives Positive EU CHMP Opinion for KEYTRUDA Plus Padcev as First-Line Treatment for Patients With Unresectable or Metastatic Urothelial Carcinoma

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/9/2026

1. META
2. SPY
3. USO
4. MSFT
5. COST
6. MU
7. IONS
8. ORCL
9. RMR
10. LEVI

Go back to Merck (MRK) Receives Positive EU CHMP Opinion for KEYTRUDA Plus Padcev as First-Line Treatment for Patients With Unresectable or Metastatic Urothelial Carcinoma
Merck & Co. (NYSE: MRK) Delayed: 125.07 -0.92 (0.73%)
Previous Close $125.99    52 Week High $65.46 
Open $125.48    52 Week Low $47.97 
Day High $128.07    P/E 85.08 
Day Low $124.45    EPS $1.47 
Volume 6,987,427